The study authors cited GLP-1-related weight loss and changes in nutritional status as risk factors for telogen effluvium, a type of non-scarring alopecia
Updated May 15, 2025
Additionally, the study looked at cardiovascular outcomes as a pre-specified secondary analysis which included a four-point composite endpoint of cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina
Blue Cross Blue Shield of Massachusetts says it will soon stop covering popular drugs for weight loss, like Ozempic and Wegovy
Ambros Labs supplies Retatrutide to qualified researchers across Canada from our Canadian inventory
PLEASE SEE OUR TERMS REGARDING YOUR RIGHTS IN ANY DISPUTE INVOLVING OUR SERVICES, INCLUDING A MANDATORY ARBITRATION CLAUSE, AND A WAIVER TO A JURY TRIAL OR CLASS ACTION, THAT LIMITS YOUR RELIEF